Arsenic Activates EGFR Pathway Signaling in the Lung

Angeline S. Andrew,*†‡ Section 1 Rebecca A. Mason,* Vincent Memoli,†‡ Eric J. Duell*†§

*Department of Community and Family Medicine, Dartmouth Medical School, Dartmouth College, Hanover, New Hampshire; Norris Cotton Cancer Center; ‡Department of Pathology, Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire; and §Genetics and Epidemiology Cluster, World Health Organization – International Agency for Research on Cancer, Lyon, France

Received December 3, 2008; accepted January 17, 2009

Arsenic is an established lung carcinogen, however, the carcinogenic mechanisms are currently under investigation. Phosphorylation of the epidermal growth factor receptor (EGFR) has been reported with arsenic exposure in bladder cells. EGFR is a tyrosine kinase transmembrane receptor that regulates important processes in carcinogenesis, including cell survival, cell cycle progression, tumor invasion, and angiogenesis. We investigated the mechanisms of EGFR pathway activation by levels of arsenic relevant to human exposure scenarios both in vitro using cultured lung epithelial cells, and in lung tumors samples from New England Lung Cancer Study participants. Toenail arsenic levels were used as an internal biomarker of arsenic exposure. Our in vitro data suggest that arsenic increases levels of the EGFR ligand, heparin binding-EGF, and activate EGFR phosphorylation in the lung. Downstream of EGFR, arsenic exposure increased pERK and cyclin D1 levels. These effects were inhibited by treatment of cultured cells with the EGFR tyrosine kinase inhibitor, Tarceva (erlotinib). In a consecutive series of human lung tumor specimens, pEGFR protein levels were higher in subjects with elevated toenail arsenic levels compared to those with low exposure (odds ratio adjusted for other factors, OR 4.1 (95% confidence interval 1.1–15.6) (p = 0.04). These data suggest that arsenic exposure may stimulate EGFR pathway activation in the lung. Moreover, the tumors that arise in arsenic-exposed individuals also exhibit signs of EGFR pathway dysregulation. Further work is needed to assess the clinical utility of targeting the EGFR pathway in subgroups of lung cancer patients who have been exposed to elevated levels of arsenic.

Key Words: epidermal growth factor; lung cancer; arsenic; cyclin D1; human.
risk of lung cancer (Travis et al., 2004). Since 15–20% of lung cancers in women and 5–10% of lung cancers in men occur in never smokers, it is also important to consider other etiologic factors and carcinogenic mechanisms in nonsmokers (Zaridze et al., 1998).

The mechanisms of arsenic carcinogenesis are an active area of investigation. At a biochemical level, arsenic can disrupt zinc finger containing protein structures (Witkiewicz-Kucharczyk and Bal, 2006) and binds to sulphydryl groups and cysteinyl residues (Suzuki et al., 2008). Arsenic induces chromosomal aberrations, aneuploidy, and micronuclei formation, but does not directly interact with DNA and is not a strong mutagen (Rossman, 2003). Arsenic also induces formation of reactive oxygen and nitrogen species (Smith et al., 2001). The known biological effects of arsenic include endocrine disruption, altered DNA repair, altered cell signaling, altered cell cycle kinetics, and alterations in proliferative response (reviewed in Rossman, 2003).

The epidermal growth factor receptor (EGFR) is a tyrosine kinase transmembrane receptor in the ErB family of receptors expressed on the surface of epithelial cells (Kari et al., 2003). A previous study demonstrated EGFR activation in lung cells at very high levels of arsenite (500µM) (Wu et al., 1999). Further work has demonstrated that both sodium arsenite and monomethylarsonous acid (MMA(III)) also induced EGFR phosphorylation in bladder cell lines (Eblin et al., 2007; Simeonova et al., 2002). EGFR is overexpressed in lung tumors and precancerous lesions, and is known to induce tumor formation in animal studies. This overexpression occurs in many tumors without gene amplification, supporting the hypothesis that exposures can modify EGFR levels (Hilbe et al., 2003).

EGFR regulates important processes in carcinogenesis, including cell survival, cell cycle progression, tumor invasion, and angiogenesis. Ligands including EGF, transforming growth factor-α (TGF-α) and Amphiregulin (Areg) bind to EGFR activating signal transduction pathways that upregulate transcription factors leading to growth stimulation (Lin et al., 2001). The EGFR pathway mediates its effects by regulating the expression of a number of target genes (Kari et al., 2003). We hypothesize that some of the biologic effects of arsenic exposure may mechanistically involve modifying signaling through the EGFR pathway. Several lines of evidence indicate that cyclin D1 is a downstream regulator in the EGFR pathway (Reissmann et al., 1999; Lin et al., 2001; Moriuchi et al., 2001; Petty et al., 2004). EGFR tyrosine kinase inhibitors (EGFR-TKI) suppress cell growth, arrest cells in G1, and decrease cyclin D1 expression in cell cultures. Therapeutic concentrations of EGFR-TKI were associated with decreased cyclin D1 and tumor necrosis in EGFR-TKI responsive patients in a small lung clinical trial (Petty et al., 2004). Cell culture studies show that EGF stimulates Ras/MAPK activity and cyclin D1 expression (Moriuchi et al., 2001). EGFR contains a transactivation domain and can bind to AT-rich consensus sites, including those found in cyclin D1, and activate transcription (Lin et al., 2001). Chromatin immunoprecipitation assays demonstrated that nuclear EGFR is associated with the cyclin D1 promoter in vivo (Lin et al., 2001). Arsenic exposure is associated with elevated cyclin D1 levels in some, but not all cell culture models (Rossman et al., 2001; Souza et al., 2001; Vogt and Rossman, 2001; Wei et al., 2002).

Defects in cell cycle control may contribute to tumorigenesis and tumor progression by allowing cells to overcome cell cycle checkpoints. Cell cycle arrest normally occurs in response to a DNA lesion to allow repair of the damaged DNA and therefore, lack of arrest decreases repair efficiency and fidelity (Sancar et al., 2004). Overexpression of cyclin D1 results in more cyclin D1-cdk4 or 6 heterodimeric complexes that phosphorylate the growth suppressor pRb. Inactivation allows Rb to release its repression of the transcription factors E2F and DP allowing them to induce transcription of cyclin E and other genes that promote cell cycle progression (Fu et al., 2004).

Therapeutic efficacy with EGFR-TKIs that block EGFR activation is observed clinically and are a recent Food and Drug Administration (FDA)–approved treatment for non–small cell lung cancer (NSCLC) (reviewed in Herbst et al., 2004). Despite this, responsiveness to this class of drugs varies dramatically between patients, and reliable predictors of the most appropriate patient subgroups remain to be identified. Motivated by the availability of these EGFR pathway inhibitors, this study of lung epithelial cells investigates the mechanisms involved in EGFR pathway activation by arsenic exposure at contamination levels relevant to the U.S. population. We test the efficacy of EGFR inhibitors in blocking arsenic-induced pathway activation and then assess the relationship between EGFR alterations in human lung tumors and biomarker-based arsenic exposure status.

**MATERIALS AND METHODS**

**Cell culture.** Human bronchial epithelial cells (Beas-2B, ATCC; Rockville, MD) were grown to postconfluence in 6- or 12-well plates (Corning Costar; Corning, NY) on VPM matrix, as previously described (Andrew and Barchowsky, 2000; Andrew et al., 2001a, b; Barchowsky et al., 2002). The cultures were maintained in LHC-9 medium (Biofluids Inc.; Rockville, MD) at 37°C under an atmosphere of 5% CO₂/95% air. Cells were then switched to KBM medium without EGF (Clonetics; Cambrex Bio Science Walkersville, Inc., Walkersville, MD) 2 h before treatment. Cells were exposed to sodium arsenite (Sigma, St Louis, MO) (0.01–10μM, which is equivalent to 0.75–750 μg/l) for a period of 24 h before harvesting for RNA isolation or protein.

**Gene expression analysis.** RNA was harvested using Trizol reagent (Gibco/BRL, Life Technologies, Gaithersburg, MD) followed by DNase digestion using DNAfree (Ambion, Inc., Austin, TX) according to the manufacturer’s instructions and quantitated by spectrophotometric absorbance at 260 nm. Real-time reverse transcription PCR (RT-PCR) was performed using gene specific primers and reagents (ABI, Foster City, CA) using the ABI PRISM sequence detection system and software. Briefly, total RNA (0.5 µg)
was reverse transcribed using 100 U M-MLV reverse transcriptase in a mixture with oligo-dT and dNTPs according to the instructions provided with the Qiagen Omniscript kit (Qiagen; Valencia, CA). Samples were reverse transcribed in a MJ Research PTC-100 thermocycler (MJ Research, Inc., Watertown, MA) for 60 min at 44°C and the reaction terminated by heating to 95°C for 10 min. Expression of HBEGF (heparin-binding EGF-like growth factor; ABI, GenBank GeneID 1839), Cyclin D1 (GenBank GeneID 595), TGF-α (GenBank 7039), and amphiregulin (GenBank 374) were assessed by real-time PCR using 10 ng total RNA, 400nM primers, 200nM probe, and TaqMan Universal PCR Master Mix (ABI). The figures are representative of at least two experiments performed with n = 3 individual cultures. Relative quantitation was performed using a standard curve consisting of serial dilutions of pooled sample cDNA from the same source as the test RNA with each plate. Relative expression levels of each gene were normalized to 18s rRNA or GAPDH (ABI).

**Protein levels.** The levels of EGFR, p-EGFR, and Cyclin D1 proteins were assessed by immunoblotting using sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-PAGE) to resolve proteins from whole cell lysates. Each figure is representative of a minimum of two experiments performed with an n = 3 individual cultures. Cells were rinsed with ice cold stop buffer (10 mmol/l Tris-HCl, pH 7.4, 10 mmol/l ethylenediaminetetraacetic acid, 5 mmol/l EGTA, 100 mmol/l NaF, 200 mmol/l sucrose, 1 μmol/l Na-orthovanadate, 5 pyrophosphate, 4 μg/ml leupeptin, 4 μg/ml soybean trypsin inhibitor, 1 μmol/l benzamidine, 20 μmol/l calpain inhibitor 1, 100 μmol/l aprotinin, and 100 μmol/l phenylmethylsulphonylfluoride). The stop buffer was then replaced with a minimal volume of 2× SDS-PAGE buffer (62.5mM Tris-HCl, pH 6.8, 10% glycerol, 2% SDS, 5% β-mercaptoethanol, 0.05% (wt/vol) bromophenol blue). The lysates were boiled for 5 min and clarified by centrifugation at 13,000 rpm for 10 min. Equal amounts of cell lysate were then resolved by electrophoresis on 8–12% SDS-polyacrylamide gels. Electrophoresis was performed at constant voltage (200 V), then the resolved proteins were transferred from the polyacrylamide gel to polyvinylidene difluoride membrane (PVDF, Immobilon-P, Millipore, Bedford, MA) by semi-dry transfer (Hoeffer Semiphor, San Fransisco, CA) for 1 h at constant current (32 mA/minigel) using transfer buffer (25mM Tris, 192mM glycine, 20% [vol/vol] methanol, 0.01% SDS). To eliminate nonspecific interactions of antibodies with the membrane, the PVDF membrane was blocked with TTBS (10mM Tris-HCl, pH 8.0, 150mM NaCl, 0.05% Tween-20) containing 5% milk (7.5 g/150 ml) for 1 h at room temperature or overnight at 4°C. Membranes were incubated with the primary EGFR, p-EGFR antibody specific to Tyr 1173, pSTAT1 (Tyro7) (Cell Signaling Technology, Danvers, MA) diluted 1:1000, or the primary Cyclin D1 antibody diluted 1:500, the pAKT (Ser473), or the pERK 1/2 (Thn202/Tyr204) antibodies diluted 1:1000 (Santa Cruz Biotechnology, Inc., Santa Cruz, CA) in TTBS overnight at 4°C. B-actin was used as a loading control diluted 1:100,000 in TTBS for 1 h (Sigma). The membranes were washed three times with TTBS. The EGFR and p-EGFR membranes were incubated with horseradish peroxidase (HRP)-linked goat anti-rabbit IgG (Santa Cruz Biotechnology, Inc.) 1:2000 in TTBS with 1% milk (0.3 g/30 ml) for 1 h at room temperature. The Cyclin D1 membrane was incubated with HRP-linked goat anti-mouse (Santa Cruz Biotechnology, Inc.) 1:3000 in TTBS with 1% milk (0.3 g/30 ml). The Secondary for B-actin was HRP-linked goat anti-mouse at 1:6000 (Bio-Rad Laboratories, Inc., Richmond, CA). After three washes with TTBS, protein bands were visualized by enhanced chemiluminescence using the Amersham ECL Plus Western Blotting Detection system (GE Healthcare, Piscataway, NJ) and film (Lumi-Film, Roche Molecular Biochemicals, Indianapolis, IN).

**Lung tumors.** Lung cancer cases include individuals with histologically confirmed NSCLC, newly diagnosed between 1/1/05 and 12/1/06 who were confirmed NSCLC, newly diagnosed between 1/1/05 and 12/1/06 who were 25–74 years of age and residents of the New England Lung Cancer Study area (ten contiguous counties of New Hampshire and Vermont) at the time of diagnosis. We obtained signed consent to access tumor specimens from these cases and received institutional human subjects approval. Immunohistochemistry was performed on a slide cut from a master lung cancer Tissue Microarray block containing tissue samples from 68 subjects using an antibody to p-EGFR or EGFR (Cell Signaling Technology, Danvers, MA). The intensity and percent of cells with membranous staining in each tumor was scored by the study pathologist, who was blinded to the arsenic exposure status of the subjects. For logistic regression analysis, positive p-EGFR staining was defined as more than 20% of cells staining at greater than 1+ intensity, which represented the top 10% percentile of staining. Toenail clipping samples collected at the time of interview were analyzed for arsenic (As, μg/g) by collision cell inductively coupled plasma mass spectrometry (ICP-MS) (750cx, Agilent, Santa Clara, CA). At the Dartmouth Trace Metals core facility. The detection limit for arsenic was approximately 0.003 μg/g.

**Statistical analysis.** Statistical analysis for gene expression and immunoblotting was performed using the ANOVA procedure with Newman-Keuls post-test (Figs. 3–5) or unpaired, two-sided t-test (Fig. 6) in GraphPad PRISM (GraphPad Software, La Jolla, CA). We considered p values less than 0.05 to be statistically significant. We conducted logistic regression analyses for positive vs. negative p-EGFR staining lung tumors in relation to arsenic exposure. Analyses were adjusted for age, gender, tumor histology, and pack-years of smoking using SAS 9.1.3 (SAS Institute, Cary, NC).

**RESULTS**

Our experiments consistently showed EGFR degradation following EGF, but not arsenic treatment (Figs. 1 and 2, row 1 EGFR). Treatment with the cycloheximide to inhibit protein synthesis further supported the observation that EGFR levels stay steady following arsenic exposure, while they degrade within the 3 h of EGF treatment. Protein synthesis inhibition alone (cycloheximide only) does not affect EGFR levels, suggesting that the receptor is not degraded unless activated by EGF (Fig. 1A). Figure 1B shows increased levels of the phosphorylated form of EGFR following treatment with arsenic (1.3, 5, and 10μM) or the positive control, EGF. Cells treated with 5μM sodium arsenite showed increased levels of EGFR phosphorylation (p-EGFR at Tyr 1173) at 3 and 5 h by immunoblot (Fig. 2, row 2, p-EGFR). The classical ligand, EGF induced EGFR phosphorylation and degradation of the receptor. We did not see changes in other phosphorylation sites in response to arsenic, including Tyr 992, 845, 1068 (data not shown). This effect was inhibited by pretreatment with the FDA-approved EGFRI-TKI drug Tarceva at clinically achievable doses. The total level of EGFR protein in Beas-2B human bronchial epithelial cells was modestly increased following arsenic exposure (Fig. 2A). We observed a significant increase in EGFR mRNA levels with EGF, but not with arsenic exposure (data not shown).

We then assessed the effects of arsenic on the cell cycle regulator cyclin D1, since it can be regulated by the EGFR pathway (Lin et al., 2001). Levels of cyclin D1 protein were elevated following 3 h arsenic and EGF (Fig. 2A, row 1 CCND1). The positive control, EGF also induced a large increase in cyclin D1 levels. Pretreatment with the EGFRI-TKI, Tarceva blocked the effects of arsenic (3 h) and EGF on cyclin D1. As reported previously, arsenic exposure increased cyclin D1 gene expression levels to those that were significantly higher than controls at 5μM for 3 h (Fig. 3).
We hypothesized that arsenic activates EGFR phosphorylation via one of its classical ligands. As shown in Figure 4A, arsenic induced the expression of the EGFR pro-ligand HB-EGF, as did EGF itself. Neither TGF-α (Fig. 4B), nor Areg (Fig. 4C) levels were modified by arsenic exposure at 4 h, yet they were induced by the positive control EGF.

We also investigated several possible signal transduction pathways immediately downstream from EGFR. We did not observe a dose-responsive increase in p-STAT1 with arsenic exposure. The positive control EGF did increase pSTAT1 levels (Fig. 5, row 1). Likewise, AKT was not significantly phosphorylated in response to either arsenic or EGF treatment, and actually decreased at the 1 and 2.5 μM arsenic doses (Fig. 5, row 2). Arsenic exposure led to increased protein levels of p-ERK that were strongest at the 5 μM dose (Fig. 5, row 3).

We then investigated the relation between arsenic exposure and EGFR pathway activation by immunohistochemistry in a consecutive series of human lung tumors. Figure 6 shows a significantly higher percent of cells staining for phospho-EGFR/EGFR in the human lung tumor specimens for subjects with elevated toenail arsenic concentration (as an internal biomarker of exposure) \((n = 68, p = 0.04)\). Although EGFR levels were slightly elevated in the high arsenic group, the difference was not statistically significant. We also assessed the association between high levels of p-EGFR staining and arsenic exposure by logistic regression, with adjustment for tumor histology, AJCC stage classification, age, gender, and pack-years of smoking. Arsenic exposure (\(> 0.05 \mu g/g\)) was associated with higher p-EGFR staining OR 4.1 (95% CI 1.1–15.6) (based on upper 75th percentile, \(n = 22\)) in comparison to subjects with low exposure (As \(< 0.05 \mu g/g, n = 46\)).

**DISCUSSION**

EGFR overexpression and pathway activation is observed in lung tumors and induces tumor formation in animal models. Some of these effects may be mediated through induction of the cell cycle promoter, cyclin D1 (Petty et al., 2003). Our data demonstrate for the first time that the EGFR pathway is activated in the human lung in response to the moderate levels of arsenic that are observed in contaminated U.S. drinking water. We used toenail arsenic levels as a long-term internal biomarker of exposure that is highly correlated with drinking water levels (Karagas et al., 2000). Our in vitro studies demonstrate that arsenic-induced phosphorylation of this receptor is prevented by pretreatment with the EGFR-TKI erlotinib/Tarceva, an FDA approved treatment for NSCLC.

Our data are consistent with the EGFR activation that was observed previously following very high level arsenic exposure (500 μM) in a study of lung cells (Wu et al. 1999). Another study reported that arsenic (50 μM) phosphorylated both EGFR and ERK in urothelial cells, however they did not see activation of the Tyr 1173 auto-phosphorylation site (Simeonova...
et al., 2002). These bladder cells also showed increased EGFR levels following long-term incubation with MMA(III) and EGFR phosphorylation within an hour of exposure (Eblin et al., 2007). Arsenic-exposed keratinocytes (200 lM) showed AKT, but not EGFR activation (Souza et al., 2001), however, EGFR activation was observed in another keratinocyte study with either 100 lM arsenite or 800 lM arsenate (Tanaka-Kagawa et al. 2003). Arsenic trioxide (20 lM) also increased p21 expression in A431 cells via activation of the EGFR/ERK pathway (Huang et al., 2006; Liu and Huang, 2006).

We observed that activation of EGFR signaling by the classical endogenous ligand, EGF, triggers rapid receptor degradation. In contrast, arsenic induced phosphorylation of the receptor at a more subtle level than EGF and the receptor was not degraded in response to activation by arsenic. Previous studies have documented that EGFRs are mono-ubiquinated soon after activation and transported to lysosomes for degradation (Lin et al., 2006; Shen et al., 2007). EGF-triggered receptor degradation is mediated by cbl, which recognizes EGFR phosphorylation and acts as the E3 ubiquitin ligase. The cdc42-associated tyrosine kinase ACK1, later colocalizes with EGFR following receptor phosphorylation on vesicles during endocytosis and acts as a ubiquitin-binding protein (Shen et al., 2007). Our phospho-specific EGFR antibody detected the phosphorylated form of the receptor. Despite an increase in EGFR mRNA levels with EGF treatment, this rapid receptor protein degradation causes the total EGFR protein level in the cell to decrease. Consistent with our in vitro studies, the lungs of arsenic-exposed lung cancer patients showed slightly higher total levels of EGFR, while pEGFR levels were significantly higher than nonexposed patients.

Classical EGFR ligands include HB-EGF, TGF-α and Areg (Kari et al., 2003). Arsenic exposure increased HB-EGF levels, suggesting that this may be an upstream mediator of EGFR pathway activation. We did not observe any effect of arsenic on TGF-α or Areg. Identifying the specific downstream target genes that are regulated by the EGFR pathway is an area of
active investigation. Consistent with previous studies in other cell types, both arsenic and EGF exposure increased p-ERK levels downstream of p-EGFR (Huang et al., 2006; Liu and Huang, 2006; Tanaka-Kagawa et al., 2003). These increases were inhibited by EGFR-TKI treatment. Several studies provide evidence that cyclin D1 is regulated by EGFR signaling (Lin et al., 2001; Moriuchi et al., 2001; Petty et al., 2004; Reissmann et al., 1999). Our data strongly support the hypothesis that arsenic increases cyclin D1 levels in part via EGFR pathway activation, and that this effect is inhibited by EGFR-TKI treatment. Previous studies have also suggested a role for Src in EGFR signaling to downstream target genes (Huang et al., 2006; Simeonova et al., 2002). Recent evidence also suggested that EGFR can regulate vascular endothelial...
growth factor (VEGF) expression via HIF-1α and Sp1. Although the hypothesized EGFR regulated genes, including VEGF, as well as p21 and HIF-1α were induced by arsenic, we did not observe EGFR-TKI inhibition of this effect (Huang et al., 2006; Liu and Huang, 2006; Pore et al., 2006).

Human plasma levels of the EGFR extracellular domain were significantly increased with arsenic exposure in a Bangladeshi population (Li et al., 2007). Likewise, we observed higher EGFR and p-EGFR protein levels in the lung tumor tissue of arsenic-exposed compared to nonexposed patients. Our in vitro work demonstrating a dose-responsive increase in total EGFR protein and mRNA levels further support this finding and suggest that arsenic-induced activation of EGFR pathway signaling in lung epithelial cells can be inhibited by treatment with EGFR-TKIs (Gschwind et al., 2004; Pao and Miller, 2005). The EGFR signaling in response to repeated drinking water arsenic exposure could lead to chronic EGFR pathway activation that could feed tumor development. This mechanism of carcinogenesis due to chronic pathway activation may be akin to that found in the lung tumors of individuals who have specific activating mutations in the tyrosine kinase domain of the EGFR (Paez et al., 2004; Pedersen et al., 2005). Additional studies are required to confirm this hypothesis.

Limitations of our lung cancer study include a small patient population and an observational study design. Nevertheless, EGFR tyrosine kinase inhibition has shown clinical utility in patient response and improved survival specifically among subsets of patients who have EGFR driven tumors (Clark et al., 2006). Data from the current study suggest that arsenic-associated lung tumors may also have EGFR pathway activation. Further work is needed to assess the clinical utility of targeting the EGFR pathway in subgroups of lung cancer patients who have been exposed to elevated levels of arsenic.

**FUNDING**

Grant numbers (CA099500, CA102327, P42 ES007373, P20 RR018787); the Institutional Development Award Program of the National Center for Research Resources, National Institutes of Health (NIH); the National Cancer Institute, NIH; and the National Institute of Environmental Health Sciences, NIH.

**ACKNOWLEDGMENTS**

Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the National Institutes of Health. We do not have any competing financial interests.

**REFERENCES**


ATSDR. (1999). Toxicological Profile for Arsenic. Agency for Toxic Substances and Disease Registry (ATSDR), Atlanta, GA.


ARSENIC ACTIVATES LUNG EGFR SIGNALING 357


